	US 12,076,393 B2
	Vaccine composition for prevention or treatment of SARS-coronavirus-2 infection
Ki-weon Seo, Gyeonggi-do (KR); Teawoo Kwon, Gyeonggi-do (KR); Eun-som Kim, Gyeonggi-do (KR); Chi-Yong Kim, Gyeonggi-do (KR); Yoonjae Lee, Gyeonggi-do (KR); and Seung-hye Hong, Gyeonggi-do (KR)
Assigned to SK BIOSCIENCE CO., LTD., Gyeonggi-do (KR)
Appl. No. 18/034,141
Filed by SK BIOSCIENCE CO., LTD., Gyeonggi-do (KR)
PCT Filed Oct. 27, 2021, PCT No. PCT/KR2021/015262 § 371(c)(1), (2) Date Aug. 30, 2023, PCT Pub. No. WO2022/092828, PCT Pub. Date May 5, 2022.
Claims priority of application No. 10-2020-0141598 (KR), filed on Oct. 28, 2020.
Prior Publication US 2024/0042008 A1, Feb. 8, 2024
Int. Cl. A61K 39/215 (2006.01); A61P 31/14 (2006.01); C07K 14/165 (2006.01); C12N 1/20 (2006.01); C12N 15/70 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [A61P 31/14 (2018.01); C07K 14/165 (2013.01); C12N 1/205 (2021.05); C12N 15/70 (2013.01); A61K 2039/55505 (2013.01)]

15 Claims

1. A pharmaceutical composition for preventing SARS-coronavirus-2 infectious disease, comprising

i. a recombinant antigen protein for preventing SARS-coronavirus-2 infectious disease, comprising a SARS-coronavirus-2 polypeptide consisting of the amino acid sequence of SEQ ID NO: 3 or 4, and a Tetanus toxoid epitope P2 polypeptide consisting of the amino acid sequence of SEQ ID NO: 1, wherein the polypeptides are linked, and

ii. one or more immunological adjuvant selected from the group consisting of aluminum hydroxide, aluminum phosphate, and hydrated aluminum potassium sulfate.